News
New weight loss pill could benefit people with Type 2 diabetes: Drugmaker
Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6% and also help people lose up to 16 pounds, or about 7.9% of their body weight.
A once-daily oral GLP-1 conferred greater reductions in HbA1c and body weight than placebo among adults with type 2 diabetes, ...
“Our CB-SCs can target different compartments of the immune system, educating and correcting their dysfunctions at a fundamental level,” says Dr. Zhao. “This therapy has the potential to revolutionize ...
Continuous glucose monitors should be considered when doctors are designing a treatment plan for people with type 2 diabetes, the researchers have said. Additionally, weight loss drugs such as Ozempic ...
Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...
Type 2 diabetes (T2D) is a complex and multifaceted disease that rarely exists in isolation. It is often entangled with a web of comorbid conditions, inclu | Immunology ...
A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.
Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...
Diabetes mellitus is most commonly known as diabetes, which is a disease that affects how the body uses glucose or blood ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback